SAN DIEGO - QuidelOrtho Corporation (NASDAQ:QDEL), a leading diagnostics company, announced significant leadership changes today, appointing Michael Iskra as interim Chief Executive Officer and Robert Bujarski as interim President. The reshuffle follows the departure of former President and CEO Douglas Bryant, who has also resigned from the Board.
The Board's decision to terminate Bryant's role was effective today and is part of a broader strategy to enhance operational efficiency and drive revenue growth. In a statement, Kenneth F. Buechler, Ph.D., Chairman of the Board, expressed gratitude to Bryant for his service and noted the need for leadership that can accelerate the company's growth initiatives.
Michael Iskra, now at the helm as interim CEO, has over three decades of experience in the diagnostics and healthcare industry, bringing a wealth of knowledge in strategy, sales, marketing, operations, and general management. Robert Bujarski, stepping in as interim President, has been with QuidelOrtho for two decades and has extensive experience across operational, commercial, and legal functions within the diagnostics sector.
The Board has commenced a comprehensive search for a permanent CEO, considering both internal and external candidates. In the interim, Iskra and Bujarski will maintain their existing executive responsibilities while taking on their new roles.
Despite the leadership transition, there is no change to the financial guidance provided by the company on February 16, 2024. However, QuidelOrtho has postponed its Investor Day, which was previously announced, to a future unspecified date.
QuidelOrtho is known for its innovative solutions in in vitro diagnostics, offering products and services that range from immunoassay and molecular testing to clinical chemistry and transfusion medicine. The company aims to deliver fast, accurate, and reliable diagnostics across various healthcare settings.
This announcement is based on a press release statement from QuidelOrtho Corporation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.